Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONCOS-102 and Chemotherapy in Malignant Pleural Mesothelioma
NCT02879669Phase 2Unknown
- Sponsor
- Targovax
- Start
- Jun 2016
- Primary completion
- May 2020
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of ONCOS-102 in malignant pleural mesothelioma (MPM), sponsored by Targovax. Status: unknown.
02
Drugs
ONCOS-102
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02879669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02879669.